Shire chief shrugs off investor protests

Drugmaker remains one of the fastest growing in its sector

Mouthwash to be life saver for babies

GSK uses ingredient in Corsodyl to treat umbilical cord infection

Valeant probes revealed in delayed report

Drugmaker staves off default on $30bn and overhauls board

Pfizer And AstraZeneca's Billion Dollar Battle...Boxes containing various pharmaceutical products are seen on display in the pharmacy department of a drugstore in London, U.K., on Friday, May 2, 2014. AstraZeneca Plc rejected Pfizer Inc.'s sweetened takeover proposal, saying the 63.1 billion-pound ($106.5 billion) offer fails to recognize the value of the promising experimental medicines under development by the U.K.'s second-biggest drugmaker. Photographer: Chris Ratcliffe/Bloomberg

AstraZeneca cuts costs for cancer drive

Pharma group moves to specialised lower-volume medicines

Pharma deals reignite M&A boom

Abbott, AbbVie and Sanofi in separate tie-ups worth $45bn


AbbVie-Stemcentrx move fuels pharma deals

Drugmaker hopes biotech will reduce reliance on blockbuster medicine

Abbott to buy St Jude in $25bn deal

Acquisition of medical devices group resumes pharma merger spree

Ackman admits fault in Valeant investment

Hedge fund billionaire in mea culpa as drug prices put under pressure

‘White House race not key to drug costs’

GSK chief says US election one of many factors adding to pressure

UBS raises $471m for cancer investment fund

Bank aims to supplement work of charities and public programmes

Sir Andrew Witty fuels GSK turnround hope

New products help offset drugs facing rise of generic competition

Africa life expectancy jumps dramatically

Longevity gains provide upbeat counterpoint to gloom on continent

Drug prices: Tweaking the formula

UK regulators are under pressure from Big Pharma as well as patients

Philips likely to list lighting business

Spin-off is consistent with plans to simplify the once-sprawling Dutch conglomerate

France’s migrant camps battle disease

A measles outbreak has sparked fears of a public health crisis at Calais and Dunkirk

Vaccine development needs a global alliance

Ebola and Zika are harbingers of a pandemic-prone era

Global health scares spark rapid innovation

Drug manufacturers are not only spending time developing new vaccines, but also on delivery methods

Vaccines deliver booster to big pharma

Developing countries offer new markets for growth

Race for universal flu vaccine gathers pace

Virologists say another severe pandemic is inevitable

Ebola vaccine development stalls post-outbreak

New doses are hard to test as incidence of the disease drops


More FT Twitter accounts